Physician profile
Richard A Smith
NPI 1730270182
$4,345.63
in general payments reported to CMS, 2019-2025
17 companies · $70.66 in 2025
The $70.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $563 · 2021: $1,593 · 2022: $378 · 2023: $423 · 2024: $299 · 2025: $70.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,337.46 | 2021 | |
| Novo Nordisk INC | $1,007.78 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $698.49 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $335.61 | 2019-2024 | |
| Amgen INC. | $183.45 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $155.33 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $134.54 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $123.04 | 2022 | |
| Supernus Pharmaceuticals, INC. | $113.73 | 2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $64.91 | 2019-2020 | |
| Shire North American Group INC | $36.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.13 | 2023-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $32.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $29.50 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $27.64 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $20.00 | 2020 | |
| Allergan, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.